Eli Lilly is returning its development and commercialization rights to Transition Therapeutics’ TT401 after opting not to advance the diabetes candidate into Phase III development. Transition, which ...

On July 24, 2023, the National Academies of Sciences, Engineering, and Medicine convened a one-day public workshop to examine challenges and opportunities for a just transition and sustainable ...